Latitude™ Tissue-Free MRD

About Natera

Natera's mission is to transform the management of cancer, pregnancy, and organ transplantation through advanced cell-free DNA analysis. The company has achieved a dominant position in minimal residual disease (MRD) testing with its Signatera™ assay, supported by over 400 peer-reviewed publications and a database of over 350,000 de-identified patient records. Its strategy centers on expanding its technology platform through acquisitions like Foresight Diagnostics, commercializing new tests like Zenith™ for rare disease, and leveraging its massive real-world data to accelerate biopharma partnerships and clinical adoption.

Therapeutic Areas